^
Association details:
| Biomarker: | EGFRvIII mutation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | AMG 595 (Microtubule inhibitor, EGFRvIII-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII
Excerpt:
In this phase 1, first-in-human, open-label, sequential-dose, exploration study, adults with recurrent GBM received AMG 595...Two patients (6%) had partial responses; 15 (47%) had stable disease….Overall, results from this study indicate that AMG 595 is a promising therapy with benefit for some patients with EGFRvIII-mutated GBM who otherwise have limited treatment options.
DOI:
https://doi.org/10.1007/s00280-019-03879-2
